CDEK
← All drugs Report issue

zg005

mAbexperimentalBi-specific

Clinical trial activity

14 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
10
Phase 2
13
Phase 3
0
Phase 4
0

Earliest trial started Jun 17, 2022 (NCT06233292)

Timeline

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Multi-specific
Yes (Bi-specific)

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07099547Phase 2Sep 30, 2025Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT07142837Phase 1/Phase 2 (Phase 2)Sep 30, 2025Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT07038096Phase 1/Phase 2 (Phase 2)Aug 31, 2025Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT07080216Phase 1/Phase 2 (Phase 2)Aug 31, 2025Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06938880Phase 1/Phase 2 (Phase 2)May 31, 2025Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06883526Phase 1/Phase 2 (Phase 2)May 31, 2025Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06927687Phase 2May 31, 2025Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06903377Phase 1/Phase 2 (Phase 2)Apr 30, 2025Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06558227Phase 2Sep 30, 2024Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06372626Phase 1/Phase 2 (Phase 2)May 30, 2024Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06239298Phase 1/Phase 2 (Phase 2)May 10, 2024Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06241235Phase 1/Phase 2 (Phase 2)Mar 27, 2024Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06233994N/AJan 31, 2024Changsha Taihe Hospital
NCT06233292Phase 1/Phase 2 (Phase 2)Jun 17, 2022Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Suzhou Zelgen Biopharmaceuticals Co.,LtdFor profit131312022
Changsha Taihe HospitalAcademic/Hospital1112024
2 organizations
Page 1 / 1